JPMorgan Arcus Biosciences (RCUS.US): Initiated at Overweight: Casdatifan Builds a Clear-Cell RCC Cornerstone, Quemliclustat Opens Pancreatic Cancer Validation
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
JPMorgan initiates coverage of Arcus Biosciences (RCUS) with an Overweight rating and a December 2027 price target of $41. The core thesis rests on Casdatifan, an oral HIF-2α inhibitor demonstrating differentiated clinical potential in clear-cell renal cell carcinoma (ccRCC), as the franchise evolves from late-line monotherapy toward a combination backbone across multiple lines of therapy. Mechanistically, VHL inactivation drives HIF-2α accumulation; Casdatifan blocks HIF-2α/HIF-1β complex formation, curbing transcription of pro-tumor genes and delivering deep, durable target inhibition. The model projects roughly $4.0 billion in global peak Casdatifan sales in 2035, including about $3.6 billion in the United States, assuming first-line ccRCC peak penetration of 40% for IO/IO combinations and 30% for IO/TKI regimens. The CD73 inhibitor Quemliclustat provides a second growth path: the Phase 3 PRISM-1 trial in first-line metastatic pancreatic ductal adenocarcinoma is expected to read out in the first half of 2027, with an interim analysis in Q4 2026 and a projected $1 billion U.S. peak in 2031. The October 20 ARC-20 investor event, disclosing first-line combination and late-line monotherapy data, is the key near-term catalyst; ARC-20 showed median PFS of 15.1 months.
Key exhibits
Exhibit 1
Exhibit 2
Exhibit 3
Exhibit 4
